BioSpace News Archive

Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments.

Amedisys, Inc. announced that Chris Gerard, President and Chief Executive Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one-on-ones at the Benchmark Healthcare House Calls Conference on Thursday, June 2, the William Blair 42nd Annual Growth Stock Conference on Monday, June 6 at 2 p.m. CST and the Jefferies Healthcare Conference on Wednesday, June 8 from 3:30-3:55 p.m. ET.

Arcutis Biotherapeutics, Inc. announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers that treat them, designed to better understand their satisfaction and experience with currently available treatment options.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Ghryvelin ™ (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults (AGHD), is now available to healthcare professionals across Europe (subject to reimbursement).

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants.

ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food and Drug Administration (FDA) clearance for its ŌNŌ retrieval system, the first major advance in endovascular bailout technology in decades.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for vonoprazan.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H. C. Wainwright Global Investment Conference 2022, a hybrid in-person/ virtual conference being held May 23rd through 26th , 2022.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will host a conference call following two poster presentations of PDS0101 data at 2022 American Society of Clinical Oncology Meeting (ASCO).

iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief Financial Officer (CFO), effective immediately.